Wall Street analysts expect that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) will report ($0.13) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for ZIOPHARM Oncology’s earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.14). ZIOPHARM Oncology reported earnings of ($0.11) per share in the same quarter last year, which would indicate a negative year over year growth rate of 18.2%. The firm is scheduled to issue its next earnings results on Wednesday, November 8th.

On average, analysts expect that ZIOPHARM Oncology will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.56) to ($0.54). For the next fiscal year, analysts expect that the business will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.65) to ($0.53). Zacks’ EPS averages are an average based on a survey of analysts that follow ZIOPHARM Oncology.

ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.66 million. During the same period last year, the company earned ($1.01) earnings per share. ZIOPHARM Oncology’s revenue for the quarter was down 5.9% on a year-over-year basis.

ZIOP has been the topic of several research reports. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. BidaskClub raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $16.50.

COPYRIGHT VIOLATION NOTICE: “ZIOPHARM Oncology Inc (ZIOP) Expected to Announce Earnings of -$0.13 Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/24/ziopharm-oncology-inc-ziop-expected-to-announce-earnings-of-0-13-per-share.html.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded down 2.54% during mid-day trading on Tuesday, reaching $4.98. 2,366,697 shares of the company’s stock were exchanged. The stock’s 50-day moving average is $6.05 and its 200-day moving average is $6.19. ZIOPHARM Oncology has a 52-week low of $4.94 and a 52-week high of $7.88. The stock’s market cap is $700.35 million.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of ZIOPHARM Oncology by 7.6% in the second quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock valued at $48,917,000 after acquiring an additional 553,933 shares during the period. State Street Corp boosted its position in shares of ZIOPHARM Oncology by 12.8% in the second quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock valued at $28,342,000 after acquiring an additional 517,057 shares during the period. Morgan Stanley boosted its position in shares of ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after acquiring an additional 324,774 shares during the period. Northern Trust Corp boosted its position in shares of ZIOPHARM Oncology by 10.1% in the second quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock valued at $10,144,000 after acquiring an additional 149,067 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of ZIOPHARM Oncology by 3.9% in the first quarter. Geode Capital Management LLC now owns 1,016,427 shares of the biotechnology company’s stock valued at $6,444,000 after acquiring an additional 38,173 shares during the period. 41.91% of the stock is owned by institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.